How to evidence market access, HTA and HEOR experience

Name the access decision

Start with the market, population, product stage and decision. Examples include evidence planning, comparator strategy, value proposition, price governance, reimbursement submission, payer engagement or implementation after recommendation. Avoid presenting regulatory approval as an access outcome.

Describe the relevant healthcare system accurately. A global strategy, national HTA submission and local formulary discussion operate at different levels. If your work informed several markets, identify the common framework and what was locally adapted.

Separate strategy, evidence and execution

Market access may define stakeholder and reimbursement strategy; HEOR may design or interpret economic, outcomes and real-world evidence; HTA specialists may assemble jurisdiction-specific submissions and manage appraisal requirements. Structures vary, but the CV should not turn collaboration into ownership of every discipline.

State whether you set the question, commissioned work, built an analysis, reviewed a model, authored a section, prepared engagement or made a recommendation. Include vendor oversight separately from technical execution so the reader can see both capabilities.

Describe the evidence boundary

Identify the clinical comparison, population, outcomes, costs or uncertainty relevant to the decision. NICE describes transparent, reproducible evidence and clear treatment of limitations as important to health technology evaluation. An application should likewise avoid presenting an assumption as an observed result.

When describing a model, specify whether you designed structure, sourced parameters, implemented calculations, validated outputs or interpreted scenarios. Submission support does not prove that the candidate personally built a functioning economic model.

Show challenge and consequence

Useful examples include a comparator challenge, evidence gap, pricing constraint, committee question or implementation barrier. Explain what changed after the challenge. A successful outcome may be recommendation or reimbursement, but it can also be a stronger evidence plan, an avoided unsupported claim or a transparent decision not to proceed.

Quantify outcomes only when attributable and shareable. National access is rarely the work of one person, so distinguish team result from personal contribution. This makes seniority and judgement easier to assess.

Build a defensible evidence statement

Use this structure: For a defined population and market, I owned or supported a named decision; I used specified evidence and stakeholder input; I recommended or delivered a governed output; the result was a verified decision or learning; remaining uncertainty was handled in a stated way.

Tailor the examples to the target role. Pricing, national access, HEOR, policy and field-access roles may sit near one another but require different proof. Unknown jurisdictional experience should remain unknown rather than being inferred from global participation.

A market-access evidence template

Record market and framework, product stage, decision population, comparator, evidence challenge, your responsibility, analysis or engagement, governance, output and consequence. Add the material uncertainty and how it was handled.

If the result was a recommendation or reimbursement milestone, distinguish the organisation’s outcome from your contribution. If the project remained pre-submission, describe the decision readiness or evidence improvement actually achieved.

Sources and further reading

Authoritative sources support the regulated or employment context. The practical framework and interpretation are original PTTF editorial work.

1. NICE health technology evaluations: the manual — NICE
2. Evidence in health technology evaluation — NICE